However, a correlation between volume of distribution and several body weight descriptors was observed, which the authors state suggest may alter concentrations in patients weighing more than 143kg ( Bhalodi AA. Papasavas PK, Tishler DS et al. Pharmacokinetics of intravenous [inezolid in moderately to morbidly obese adults.
https://www.networks.nhs.uk/nhs-networks/association-of-scottish-antimicrobial-pharmacists/messageboard/trial-of-nhs-networks-for-asap/58693253/527721847/ukmi-q-and-a
Some studies suggest that adjusted body weight (AdjBW) with a correction factor of 0.4 is most accurate, whilst other studies and the UKCPA suggest the use of lean body weight.
https://www.networks.nhs.uk/nhs-networks/association-of-scottish-antimicrobial-pharmacists/messageboard/trial-of-nhs-networks-for-asap/58693253/527721847/ukmi-q-and-a
The British National Formulary (BNF) advises that IBW is used to calculate the doses of aminoglycosides in obese patients with close monitoring of the serum concentrations (11). However several authors and studies indicate initial aminoglycoside doses should be based on AdjBW, with an interval appropriate for the estimated renal function.
https://www.networks.nhs.uk/nhs-networks/association-of-scottish-antimicrobial-pharmacists/messageboard/trial-of-nhs-networks-for-asap/58693253/527721847/ukmi-q-and-a
doc for "acyclovir adjusted body weight".(Page 1 of about 17 results)